Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review

被引：0
|
作者：
Zohreh Maghsoomi
Zahra Emami
Ramin Malboosbaf
Mojtaba Malek
Mohammad E. Khamseh
机构：
[1] Iran University of Medical Science (IUMS),Endocrine Research Center, Institute of Endocrinology and Metabolism
[2] Iran University of Medical Sciences (IUMS),Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism
来源：
BMC Cancer | / 21卷
关键词：
Peptide receptor radionuclide therapy; Radioiodine refractory-differentiated thyroid Cancer; Medullary thyroid carcinoma; Papillary thyroid carcinoma; Yttrium-90; 177Lu-DOTATATE; Indium-111; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Reply: Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials
    Su, Jingyang
    Fu, Yue
    Wang, Menglei
    Lin, Shengyou
    CLINICAL ENDOCRINOLOGY, 2023, 98 (02) : 275 - 276
  • [22] Effectiveness of radioiodine therapy on preventing recurrence in differentiated thyroid carcinoma: a systematic review
    Bima Indra
    Nur Qodir
    Didit Pramudhito
    Legiran Legiran
    Zen Hafy
    Andi M Iqbal Yusran
    Journal of the Egyptian National Cancer Institute, 37 (1)
  • [23] Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review
    Chou, Roger
    Dana, Tracy
    Haymart, Megan
    Leung, Angela M.
    Tufano, Ralph P.
    Sosa, Julie Ann
    Ringel, Matthew D.
    THYROID, 2022, 32 (04) : 351 - 367
  • [24] Systemic treatment of advanced differentiated and medullary thyroid cancer Overview and practical aspects
    Kreissl, M. C.
    Fassnacht, M.
    Mueller, S. P.
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2015, 54 (03): : 88 - 93
  • [25] Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer
    Sun, Yongkun
    Du, Feng
    Gao, Ming
    Ji, Qinghai
    Li, Zhendong
    Zhang, Yuan
    Guo, Zhuming
    Wang, Jun
    Chen, Xiangjin
    Wang, Jinwan
    Chi, Yihebali
    Tang, Pingzhang
    THYROID, 2018, 28 (11) : 1455 - 1461
  • [26] A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
    Nigel Fleeman
    Rachel Houten
    Marty Chaplin
    Sophie Beale
    Angela Boland
    Yenal Dundar
    Janette Greenhalgh
    Rui Duarte
    Aditya Shenoy
    BMC Cancer, 19
  • [27] A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
    Fleeman, Nigel
    Houten, Rachel
    Chaplin, Marty
    Beale, Sophie
    Boland, Angela
    Dundar, Yenal
    Greenhalgh, Janette
    Duarte, Rui
    Shenoy, Aditya
    BMC CANCER, 2019, 19 (01)
  • [28] Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
    Trimboli, Pierpaolo
    Castellana, Marco
    Virili, Camilla
    Giorgino, Francesco
    Giovanella, Luca
    FRONTIERS IN ENDOCRINOLOGY, 2018, 9
  • [29] Systematic review of site distribution of bone metastases in differentiated thyroid cancer
    Osorio, Marcela
    Moubayed, Sami P.
    Su, Henry
    Urken, Mark L.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (04): : 812 - 818
  • [30] Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
    Enrique Grande
    Michael C. Kreissl
    Sebastiano Filetti
    Kate Newbold
    Walter Reinisch
    Caroline Robert
    Martin Schlumberger
    Lærke K. Tolstrup
    Jose L. Zamorano
    Jaume Capdevila
    Advances in Therapy, 2013, 30 : 945 - 966
12345